Skin and Soft Tissue
Phase III
Accepting Patients
nct/study# NCT03486873 / MK3475-587
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Learn More
Skin and Soft Tissue
Phase III
Accepting Patients
nct/study# NCT03833167 / MK-3475-630
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCCC) (KEYNOTE-630)
Learn More
Skin and Soft Tissue
Phase II
Accepting Patients
nct/study# NCT03897881 / MRNA-4157-P201
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)
Learn More
Skin and Soft Tissue
Phase III
Accepting Patients
nct/study# NCT04410445 / 20-214-29/CA045-022
A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Learn More
Skin and Soft Tissue
Phase II
Accepting Patients
nct/study# NCT04050436 / RPL-002-18
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Learn More
Skin and Soft Tissue
Phase II
Accepting Patients
nct/study# NCT03698019 / S1801
A Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High Risk Melanoma.
Learn More
